<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170376</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-124</org_study_id>
    <nct_id>NCT02170376</nct_id>
  </id_info>
  <brief_title>The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics</brief_title>
  <official_title>The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics When Administered With Immediate-release 100/25 mg Levodopa/Carbidopa in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50
      and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK),
      in comparison to placebo and 200 mg entacapone (ENT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a single-centre, randomized, double-blind, gender-balanced, placebo-controlled
      study in 4 groups of 20 healthy subjects each (10 male and 10 female). The clinical part
      included a screening examination within 3 weeks before the first institutionalization, an
      ambulatory period of 11 days (from Day 1 evening to Day 11 evening), during which the
      subjects returned to the clinical unit every evening, followed by an institutionalization of
      1.5 days (from Day 11 evening to Day 13 morning (i.e. 14 h after the third administration of
      levodopa/carbidopa). Then, a follow-up visit at 5 to 9 days after collection of the last PK
      blood sample (i.e. Day 13). The maximum total duration of the clinical study, including the
      21-day screening period and the post-study follow-up, was expected to be about 39 to 43 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Plasma Concentration of Levodopa</measure>
    <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
    <description>Cmax - Maximum plasma concentration of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time of Occurrence of Maximum Plasma Concentration</measure>
    <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
    <description>Tmax - Time to Reach maximum plasma concentration of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - Area Under the Concentration-time Curve From Time Zero up to Infinity With Extrapolation of the Terminal Phase</measure>
    <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
    <description>AUC0-∞ of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Time (t) Corresponding to the Last Quantifiable Concentration.</measure>
    <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
    <description>AUC0-t - of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-5 - AUC Over 5 Hours</measure>
    <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
    <description>AUC0-5 - of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 - Terminal Plasma Half-life</measure>
    <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
    <description>t1/2 - Terminal plasma half-life of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Parkinson's Disease (PD)</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>BIA 9-1067 25 mg and 50 mg</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Opicapone, OPC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entacapone</intervention_name>
    <description>Entacapone (ENT), over-encapsulated tablet 200 mg</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Comtan®, ENT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PLC, placebo</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <other_name>PLC, placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/carbidopa</intervention_name>
    <description>Levodopa/carbidopa, tablet 100/25 mg</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <other_name>Sinemet®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers 18 to 45 years old (inclusive),

          -  Body Mass Index (BMI) in normal range (18-30 kg/m²),

          -  Healthy as determined by the Investigator on the basis of medical history, physical
             examination, clinical laboratory test results, vital signs, complete neurological
             examination and 12-lead ECG (electrocardiogram),

          -  Negative tests for Hepatitis B surface antigen (HBsAG), anti-Hepatitis C virus (HCV)
             antibodies and Human immunodeficiency virus (HIV) -1 and HIV-2 antibodies at
             screening,

          -  Negative screen for drugs of abuse and alcohol at screening and admission to the
             treatment period,

          -  If of childbearing potential (i.e. except if they had been sterilized for at least 3
             months or postmenopausal for at least one year - the menopause was defined by a
             follicule stimulating hormone (FSH) level &gt; 30 IU/L): used a non hormonal acceptable
             contraception method, i.e. intra-uterine device, condom or occlusive cap (diaphragm or
             cervical/vault caps) with spermicidal foam/gel/film/cream/suppository for all the
             duration of the study,

          -  If female of childbearing potential, had a negative human chorionic gonadotropin (HCG)
             beta serum pregnancy test at screening and urinary pregnancy test at admission to both
             ambulatory and confinement periods,

          -  Non-smokers or ex-smokers for at least 3 months,

          -  Able to communicate well with the Investigator and research staff and to comply with
             the requirements of the entire study,

          -  Provision of written informed consent to participate as shown by a signature on the
             volunteer consent form,

          -  Registered with the French Social Security in agreement with the French law on
             biomedical experimentation

        Exclusion Criteria:

          -  Did not conform to the above inclusion criteria, or in case of volunteers who had a
             clinically relevant surgical history, a clinically relevant family history; had a
             history of relevant atopy,

          -  Had a significant infection or known inflammatory process at screening or admission to
             the treatment period; acute gastrointestinal symptoms (e.g., nausea, vomiting,
             diarrhoea, heartburn) at the time of screening or admission to the treatment period,

          -  Were vegetarians, vegans or had medical dietary restrictions,

          -  Could not communicate reliably with the Investigator,

          -  Were unlikely to co-operate with the requirements of the study; history of
             hypersensitivity to OPC, tolcapone, ENT, levodopa, carbidopa, benserazide or any
             related products (including excipients of the formulations) as well as severe
             hypersensitivity reactions (like angioedema) to any drugs,

          -  Had any significant cardiovascular (e.g. hypertension), hepatic, renal, respiratory
             (e.g. childhood asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia),
             immunologic, dermatological, hematological, neurological, or psychiatric disease,

          -  Presented any clinically significant illness in the previous 28 days before Day 1 of
             this study; history of drug abuse within 1 year before study Day 1; history of
             alcoholism within 1 year before Day 1,

          -  Had taken any prescribed or over the counter drug (including antacid drug), with the
             exception of paracetamol (up to 3 g per day) within 2 weeks prior to the dose
             administration,

          -  Consumed more than 50 g of ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4
             cL of aperitif, 42° [42%] whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL
             glass of 6° [6%] beer = 15 g,

          -  Drank more than 8 cups daily of beverage containing caffeine,

          -  Had poor motivation, intellectual problems likely to limit the validity of consent to
             participate in the study or limit the ability to comply with the protocol requirements
             or inability to cooperate adequately, inability to understand and to observe the
             instructions of the physician,

          -  Had received any experimental drug within the exclusion period defined in the National
             Register for Healthy Volunteers of the French Ministry of Health,

          -  Forfeited their freedom by administrative or legal award or were under guardianship,

          -  Had undergone surgery or had donated blood (i.e. 450 mL) within 12 weeks before study
             Day 1,

          -  Had positive urine screening of ethyl alcohol or drugs of abuse upon admission to the
             treatment period,

          -  Had any history of tuberculosis and/or prophylaxis for tuberculosis; positive results
             to HIV, HBsAg or anti-HCV tests; participation in any previous clinical study with
             OPC,

          -  If female, was pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SGS aster</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <results_first_submitted>July 22, 2015</results_first_submitted>
  <results_first_submitted_qc>July 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 20, 2016</results_first_posted>
  <last_update_submitted>July 29, 2016</last_update_submitted>
  <last_update_submitted_qc>July 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease (PD)</keyword>
  <keyword>BIA 9-1067</keyword>
  <keyword>Opicapone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Opicapone</mesh_term>
    <mesh_term>Entacapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Placebo Then Entacapone/Levodopa</title>
          <description>Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
Entacapone: Entacapone (ENT), over-encapsulated tablet 200 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="P2">
          <title>Group 2: BIA 25 mg Then Placebo/Levodopa/Carbidopa</title>
          <description>25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
BIA 9-1067: BIA 9-1067 25 mg and 50 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="P3">
          <title>Group 3: BIA 50 mg Then Placebo/Levodopa/Carbidopa</title>
          <description>50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
BIA 9-1067: BIA 9-1067 25 mg and 50 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="P4">
          <title>Group 4: BIA 75 mg Then Placebo/Levodopa/Carbidopa</title>
          <description>75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
BIA 9-1067: BIA 9-1067 25 mg and 50 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="P5">
          <title>Group 5: Placebo Then Levodopa/Carbidopa</title>
          <description>placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic Population</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
Entacapone: Entacapone (ENT), over-encapsulated tablet 200 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
BIA 9-1067: BIA 9-1067 25 mg and 50 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
BIA 9-1067: BIA 9-1067 25 mg and 50 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
BIA 9-1067: BIA 9-1067 25 mg and 50 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="B5">
          <title>Group 5</title>
          <description>placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="16"/>
            <count group_id="B6" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Plasma Concentration of Levodopa</title>
        <description>Cmax - Maximum plasma concentration of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
        <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: PLC, placebo</description>
          </group>
          <group group_id="O2">
            <title>OPC 25 mg</title>
            <description>OPC: BIA 9-1067 25 mg</description>
          </group>
          <group group_id="O3">
            <title>OPC 50 mg</title>
            <description>OPC: BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O4">
            <title>OPC 75 mg</title>
            <description>OPC: BIA 9-1067 25 mg and 50 mg</description>
          </group>
          <group group_id="O5">
            <title>ENT 200 mg</title>
            <description>Entacapone (ENT), over-encapsulated tablet 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Plasma Concentration of Levodopa</title>
          <description>Cmax - Maximum plasma concentration of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1047" spread="340"/>
                    <measurement group_id="O2" value="1203" spread="453"/>
                    <measurement group_id="O3" value="1030" spread="400"/>
                    <measurement group_id="O4" value="1057" spread="335"/>
                    <measurement group_id="O5" value="876" spread="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Second Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1550" spread="542"/>
                    <measurement group_id="O2" value="1619" spread="762"/>
                    <measurement group_id="O3" value="1974" spread="847"/>
                    <measurement group_id="O4" value="2113" spread="868"/>
                    <measurement group_id="O5" value="1437" spread="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Third Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1268" spread="532"/>
                    <measurement group_id="O2" value="1393" spread="627"/>
                    <measurement group_id="O3" value="1346" spread="337"/>
                    <measurement group_id="O4" value="1658" spread="435"/>
                    <measurement group_id="O5" value="1303" spread="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time of Occurrence of Maximum Plasma Concentration</title>
        <description>Tmax - Time to Reach maximum plasma concentration of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone</description>
        <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: PLC, placebo</description>
          </group>
          <group group_id="O2">
            <title>OPC 25 mg</title>
            <description>OPC: BIA 9-1067 25 mg</description>
          </group>
          <group group_id="O3">
            <title>OPC 50 mg</title>
            <description>OPC: BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O4">
            <title>OPC 75 mg</title>
            <description>OPC: BIA 9-1067 25 mg and 50 mg</description>
          </group>
          <group group_id="O5">
            <title>ENT 200 mg</title>
            <description>Entacapone (ENT), over-encapsulated tablet 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time of Occurrence of Maximum Plasma Concentration</title>
          <description>Tmax - Time to Reach maximum plasma concentration of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.854"/>
                    <measurement group_id="O2" value="1.13" spread="0.790"/>
                    <measurement group_id="O3" value="1.34" spread="1.01"/>
                    <measurement group_id="O4" value="1.28" spread="0.515"/>
                    <measurement group_id="O5" value="1.13" spread="0.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Second Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.875" spread="0.465"/>
                    <measurement group_id="O2" value="1.20" spread="0.862"/>
                    <measurement group_id="O3" value="1.06" spread="0.892"/>
                    <measurement group_id="O4" value="1.19" spread="0.854"/>
                    <measurement group_id="O5" value="0.906" spread="0.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Third Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.964"/>
                    <measurement group_id="O2" value="1.33" spread="0.699"/>
                    <measurement group_id="O3" value="1.34" spread="0.65"/>
                    <measurement group_id="O4" value="1.31" spread="0.854"/>
                    <measurement group_id="O5" value="1.59" spread="0.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ - Area Under the Concentration-time Curve From Time Zero up to Infinity With Extrapolation of the Terminal Phase</title>
        <description>AUC0-∞ of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
        <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: PLC, placebo</description>
          </group>
          <group group_id="O2">
            <title>OPC 25 mg</title>
            <description>OPC: BIA 9-1067 25 mg</description>
          </group>
          <group group_id="O3">
            <title>OPC 50 mg</title>
            <description>OPC: BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O4">
            <title>OPC 75 mg</title>
            <description>OPC: BIA 9-1067 25 mg and 50 mg</description>
          </group>
          <group group_id="O5">
            <title>ENT 200 mg</title>
            <description>Entacapone (ENT), over-encapsulated tablet 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ - Area Under the Concentration-time Curve From Time Zero up to Infinity With Extrapolation of the Terminal Phase</title>
          <description>AUC0-∞ of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2305" spread="391"/>
                    <measurement group_id="O2" value="3732" spread="1418"/>
                    <measurement group_id="O3" value="3363" spread="1042"/>
                    <measurement group_id="O4" value="3998" spread="1275"/>
                    <measurement group_id="O5" value="2752" spread="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Second Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3070" spread="396"/>
                    <measurement group_id="O2" value="4967" spread="2003"/>
                    <measurement group_id="O3" value="5727" spread="1495"/>
                    <measurement group_id="O4" value="6213" spread="1440"/>
                    <measurement group_id="O5" value="4367" spread="1463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Third Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3299" spread="433"/>
                    <measurement group_id="O2" value="5614" spread="2467"/>
                    <measurement group_id="O3" value="5912" spread="1478"/>
                    <measurement group_id="O4" value="7177" spread="1835"/>
                    <measurement group_id="O5" value="4707" spread="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Time (t) Corresponding to the Last Quantifiable Concentration.</title>
        <description>AUC0-t - of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
        <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: PLC, placebo</description>
          </group>
          <group group_id="O2">
            <title>OPC 25 mg</title>
            <description>OPC: BIA 9-1067 25 mg</description>
          </group>
          <group group_id="O3">
            <title>OPC 50 mg</title>
            <description>OPC: BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O4">
            <title>OPC 75 mg</title>
            <description>OPC: BIA 9-1067 25 mg and 50 mg</description>
          </group>
          <group group_id="O5">
            <title>ENT 200 mg</title>
            <description>Entacapone (ENT), over-encapsulated tablet 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Time (t) Corresponding to the Last Quantifiable Concentration.</title>
          <description>AUC0-t - of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1985" spread="346"/>
                    <measurement group_id="O2" value="2665" spread="867"/>
                    <measurement group_id="O3" value="2383" spread="699"/>
                    <measurement group_id="O4" value="2829" spread="794"/>
                    <measurement group_id="O5" value="2041" spread="671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Second Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2774" spread="353"/>
                    <measurement group_id="O2" value="3678" spread="1455"/>
                    <measurement group_id="O3" value="4151" spread="1070"/>
                    <measurement group_id="O4" value="4597" spread="1041"/>
                    <measurement group_id="O5" value="3445" spread="1128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Third Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3123" spread="447"/>
                    <measurement group_id="O2" value="5391" spread="2444"/>
                    <measurement group_id="O3" value="5685" spread="1466"/>
                    <measurement group_id="O4" value="6928" spread="1797"/>
                    <measurement group_id="O5" value="4366" spread="1426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-5 - AUC Over 5 Hours</title>
        <description>AUC0-5 - of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
        <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: PLC, placebo</description>
          </group>
          <group group_id="O2">
            <title>OPC 25 mg</title>
            <description>OPC: BIA 9-1067 25 mg</description>
          </group>
          <group group_id="O3">
            <title>OPC 50 mg</title>
            <description>OPC: BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O4">
            <title>OPC 75 mg</title>
            <description>OPC: BIA 9-1067 25 mg and 50 mg</description>
          </group>
          <group group_id="O5">
            <title>ENT 200 mg</title>
            <description>Entacapone (ENT), over-encapsulated tablet 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-5 - AUC Over 5 Hours</title>
          <description>AUC0-5 - of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1985" spread="346"/>
                    <measurement group_id="O2" value="2665" spread="867"/>
                    <measurement group_id="O3" value="2383" spread="699"/>
                    <measurement group_id="O4" value="2829" spread="794"/>
                    <measurement group_id="O5" value="2042" spread="669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Second Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2774" spread="353"/>
                    <measurement group_id="O2" value="3678" spread="1455"/>
                    <measurement group_id="O3" value="4151" spread="1070"/>
                    <measurement group_id="O4" value="4597" spread="1041"/>
                    <measurement group_id="O5" value="3446" spread="1125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Third Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2719" spread="492"/>
                    <measurement group_id="O2" value="3802" spread="1549"/>
                    <measurement group_id="O3" value="3940" spread="1022"/>
                    <measurement group_id="O4" value="4882" spread="1246"/>
                    <measurement group_id="O5" value="3468" spread="1108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 - Terminal Plasma Half-life</title>
        <description>t1/2 - Terminal plasma half-life of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
        <time_frame>pre-first dose and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 5.0 h post-first and -second levodopa/carbidopa administration, and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 8.0 and 14.0 h post-third levodopa/carbidopa administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: PLC, placebo</description>
          </group>
          <group group_id="O2">
            <title>OPC 25 mg</title>
            <description>OPC: BIA 9-1067 25 mg</description>
          </group>
          <group group_id="O3">
            <title>OPC 50 mg</title>
            <description>OPC: BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O4">
            <title>OPC 75 mg</title>
            <description>OPC: BIA 9-1067 25 mg and 50 mg</description>
          </group>
          <group group_id="O5">
            <title>ENT 200 mg</title>
            <description>Entacapone (ENT), over-encapsulated tablet 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 - Terminal Plasma Half-life</title>
          <description>t1/2 - Terminal plasma half-life of levodopa (mean pharmacokinetic parameter) following first oral administration of 100/25 mg levodopa/carbidopa on Day 12 with 25, 50 and 75 mg OPC or placebo and 200 mg Entacapone.</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.406"/>
                    <measurement group_id="O2" value="2.47" spread="0.830"/>
                    <measurement group_id="O3" value="2.47" spread="0.098"/>
                    <measurement group_id="O4" value="2.39" spread="0.556"/>
                    <measurement group_id="O5" value="2.11" spread="0.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Second Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.136"/>
                    <measurement group_id="O2" value="2.23" spread="0.385"/>
                    <measurement group_id="O3" value="2.46" spread="0.312"/>
                    <measurement group_id="O4" value="2.23" spread="0.513"/>
                    <measurement group_id="O5" value="2.09" spread="0.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Third Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.349"/>
                    <measurement group_id="O2" value="2.56" spread="0.440"/>
                    <measurement group_id="O3" value="2.75" spread="0.513"/>
                    <measurement group_id="O4" value="2.70" spread="0.462"/>
                    <measurement group_id="O5" value="2.20" spread="0.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
Entacapone: Entacapone (ENT), over-encapsulated tablet 200 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
BIA 9-1067: BIA 9-1067 25 mg and 50 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
BIA 9-1067: BIA 9-1067 25 mg and 50 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
BIA 9-1067: BIA 9-1067 25 mg and 50 mg
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
        <group group_id="E5">
          <title>Group 5</title>
          <description>placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
Placebo: PLC, placebo
Levodopa/carbidopa: Levodopa/carbidopa, tablet 100/25 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pityriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold Sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Varicophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

